Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 5/20 | 0.47 |
| ▸ | MMP9 | P14780 | 4/20 | 0.47 |
| ▸ | CTSC | P53634 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9439449 | 0.84 | CTSC (0.58) | MMENPSR1CYP1A2CTSC | |
| Hydrochloric Acid SCHEMBL9439452 | 0.84 | CTSC (0.58) | MMENPSR1CYP1A2CTSC | |
| SCHEMBL9068541 | 0.84 | MME (0.70) | MMENPSR1ALPIPKMPTGS1 | |
| SCHEMBL7379335 | 0.84 | MME (0.70) | MMENPSR1ALPIPKMPTGS1 | |
| SCHEMBL8835601 | 0.77 | MME (0.58) | MMENPSR1NAALAD2CYP1A2MMP2 | |
| SCHEMBL2781126 | 0.77 | MME (0.58) | MMENPSR1NAALAD2CYP1A2L3MBTL1 | |
| SCHEMBL123574 | 0.77 | MME (0.58) | MMENPSR1NAALAD2CYP1A2L3MBTL1 | |
| SCHEMBL3506387 | 0.77 | MME (0.58) | MMENPSR1NAALAD2CYP1A2MMP2 | |
| SCHEMBL8835606 | 0.77 | MME (0.58) | MMENPSR1NAALAD2CYP1A2MMP2 | |
| SCHEMBL15592756 | 0.77 | MME (0.58) | MMENPSR1NAALAD2CYP1A2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993631-B2 | Method of treating contrast-induced nephropathy | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-20140336194-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2014-11-13 | — | — | US | disclosed |
| EP-2640375-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | Novartis AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012065958-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| EP-0054862-B1 | SUBSTITUTED DIPEPTIDES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE INHIBITION OF ENKEPHALINASE | SCHERING CORPORATION (US) | 1985-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336194-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | MME 3/4885NPSR1 266/4885ALPI 1074/4885 |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | MME 3/4885NPSR1 266/4885ALPI 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.